Trials of this treatment against these cancers used immune checkpoint therapy with various targets on the cellular surface, such as cytotoxic-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 or its ligand (PD-1/L1) [3]. Here, PDCD1 is linked to cancer.